- Home
- RMNI vs ABOS Comparison
RMNI vs ABOS Comparison
Compare RMNI & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMNI
- ABOS
- Stock Information
- Founded
- RMNI 2005
- ABOS 1996
- Country
- RMNI United States
- ABOS United States
- Employees
- RMNI N/A
- ABOS N/A
- Industry
- RMNI Business Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- RMNI Consumer Discretionary
- ABOS Health Care
- Exchange
- RMNI Nasdaq
- ABOS Nasdaq
- Market Cap
- RMNI 178.7M
- ABOS 171.8M
- IPO Year
- RMNI N/A
- ABOS 2021
- Fundamental
- Price
- RMNI $1.93
- ABOS $2.31
- Analyst Decision
- RMNI Hold
- ABOS Strong Buy
- Analyst Count
- RMNI 1
- ABOS 4
- Target Price
- RMNI N/A
- ABOS $9.00
- AVG Volume (30 Days)
- RMNI 327.3K
- ABOS 213.7K
- Earning Date
- RMNI 10-30-2024
- ABOS 11-12-2024
- Dividend Yield
- RMNI N/A
- ABOS N/A
- EPS Growth
- RMNI N/A
- ABOS N/A
- EPS
- RMNI N/A
- ABOS N/A
- Revenue
- RMNI $426,650,000.00
- ABOS N/A
- Revenue This Year
- RMNI N/A
- ABOS N/A
- Revenue Next Year
- RMNI N/A
- ABOS N/A
- P/E Ratio
- RMNI N/A
- ABOS N/A
- Revenue Growth
- RMNI N/A
- ABOS N/A
- 52 Week Low
- RMNI $1.53
- ABOS $2.08
- 52 Week High
- RMNI $3.44
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- RMNI 54.33
- ABOS 38.80
- Support Level
- RMNI $1.84
- ABOS $2.23
- Resistance Level
- RMNI $1.99
- ABOS $2.45
- Average True Range (ATR)
- RMNI 0.09
- ABOS 0.24
- MACD
- RMNI 0.01
- ABOS -0.09
- Stochastic Oscillator
- RMNI 66.67
- ABOS 7.08
About RMNI Rimini Street Inc. (DE)
Rimini Street Inc is a provider of enterprise software support products and services and a third-party support provider for Oracle and SAP software products based in the United States. The company offers solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. Some of its products include Oracle E-business suite, Oracle Database, Peoplesoft, SAP business suite, and others. The company derives maximum revenue from United states.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.